Coverage with evidence development (CED) is a reimbursement mechanism the Centers for Medicare and Medicaid Services (CMS) is increasingly using for new technologies.1 The September 2013 CMS coverage decision for amyloid positron-emission tomography (PET) indicated that amyloid PET imaging under most circumstances will not be reimbursed. Reimbursement is possible only through CED in a CMS-approved study. Thus, many neurologists for the first time will face the decision of whether to participate in CED. We hope that sharing our experience with CED for use of 18fluorodeoxyglucose (FDG)-PET in the treatment of mild cognitive impairment through the Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID) Study (eAppendix 1 in Supplement) will be instructive.
Foster NL, Mottola K, Hoffman JM. Coverage With Evidence DevelopmentWhat to Consider. JAMA Neurol. 2014;71(4):399–400. doi:10.1001/jamaneurol.2013.5812